GLP-1 are extraordinary drugs that are having a remarkable impact on public health. This is a very good thing. Almost every medical condition we can think of gets better when one loses weight. This too is a good thing. But this study does not show GLP-1 reduced cancer rates and its methodology is deeply flawed. The likeliest explanation for these retrospective data analysis is that women with access to healthcare that covers expensive GLP-1 medications have better healthcare outcomes including in cancer care. If you want to be a bit more daring, you could hypothesize that women who lose weight do better with breast cancer. That's not a crazy hypothesis (although the paper can't prove it). But the idea that GLP-1 have some sort of anti-cancer MOA is not supported by this paper. And yet that is the narrative being created here. There is a plague of such papers out there and editors and reviewers are seemingly perfectly fine with it. That is going to backfire at some stage.
A new study of more than 111,000 women ages 45 to 80 found those on GLP-1 medications had a reduced risk of developing breast cancer by about 30%.
abcnews.link/ZTUh9eG